Small molecules as PD-1/PD-L1 pathway modulators for cancer immunotherapy.

Small molecules as PD-1/PD-L1 pathway modulators for cancer immunotherapy. Curr Pharm Des. 2018 Nov 11;: Authors: Jiao P, Geng Q, Jin P, Su G, Teng H, Dong J, Yan B Abstract Blockade of PD-1/PD-L1 interaction using PD-1/PD-L1 inhibitors have demonstrated unprecedented clinical efficacy in various cancer types. Current PD-1/PD-L1 inhibitors approved by FDA are exclusively dominated by therapeutic antibodies. However, therapeutic antibodies also exhibit several disadvantages such as low tumor tissues penetration, difficult across physiological barriers, lacking oral bioavailability, immunogenicity, long half-life time and strong target occupancy, high manufacturing costs, inaccessible to intracellular targets. Modulation of PD-1/PD-L1 pathway using small molecules may be an alternative approach to mobilize immune system to fight with cancers. In this review, we focus on addressing the disclosed chemical structures and preliminary structure-activity relationships of small molecules in recent patents. PMID: 30417781 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research